Infektionskrankheit

The Infectious Disease theme encompasses companies developing prevention, detection, and treatment solutions for viral, bacterial, and emerging pathogens. Core tracks include vaccines and platform technologies (mRNA, viral vectors), anti-infective therapeutics and monoclonal antibodies, rapid and molecular diagnostics, genomic surveillance and biosecurity, hospital infection control and sterilization, and public-health data analytics and distribution, spanning the value chain from research and clinical trials to manufacturing, point-of-care testing, and outbreak response.The sector's total market cap is 2359.14 billion USD, with a 24h change of +1.20%. Among 16 constituents, 15 are up (93.75%) and 1 are down (6.25%). The top gainer is Moderna, Inc. (MRNA), with a 24h increase of +4.29%.Sector gains led by diagnostics/tools leaders; flows concentrate in quality large caps as smaller names diverge. Near term, trade leaders on momentum; medium term, add on earnings clarity and rate dips.